“One of the biggest problems in the treatment of depression today is a delay in onset of therapeutic effects”
More than 1 in 10 Americans take antidepressants, but these medications can take weeks—and for some patients, months—before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.
“One of the biggest problems in the treatment of depression today is a delay in onset of therapeutic effects. There has been a great need to discover faster-acting drugs,” said Stephanie Dulawa, PhD, associate professor of psychiatry and behavioral neuroscience at the University of Chicago and senior author of the study.
Delayed onset of antidepressant therapeutics can significantly impact patients, especially those with major depressive disorder, who often spend months switching between ineffective medications. Currently, only two drugs—ketamine and scopolamine—exhibit rapid onset. Due to severe side effects, however, neither is suitable for human use.
In seeking a new class of fast-acting therapeutics, Dulawa and her team tested biological pathways that had previously been shown to generate antidepressant effects but had never been studied for rate of onset. They looked at different subtypes of serotonin receptors, proteins that are binding partners for serotonin, a neurotransmitter that has been shown to regulate mood, memory and appetite.
Of these subtypes, serotonin 2C receptors stood out. Selectively blocking these receptors in mice significantly reduced depression-like behaviors in only five days, compared to a minimum of two weeks for a control antidepressant medication.
“We observed fast-acting therapeutic effects in multiple behavioral tasks after we administered compounds that selectively block serotonin 2C receptors,” said Mark Opal, a graduate student at the University of Chicago and lead author of the paper. “We began our measurements at five days, but we think there’s a possibility it could be effective even sooner than that.”
Serotonin 2C receptors normally inhibit the release of dopamine, another neurotransmitter commonly associated with mood, from certain neurons. When 2C is blocked, the researchers believe, more dopamine is released into regions of the brain such as the prefrontal cortex. The team also observed the induction of biomarkers that indicate antidepressant action.
This is the first new biological mechanism that has shown the ability to rapidly alleviate symptoms of depression since ketamine and scopolamine, and it potentially represents a much safer alternative.
Go deeper with Bing News on:
- Silencil Reviews – Real Ear Ringing Tinnitus Relief or Fake Formula?on January 22, 2021 at 4:29 pm
People across the country experience ringing in their ears for unknown reasons, and that ringing wouldn’t go away no matter what they did. No amount of consultations with the doctor worked, and the ...
- Antidepressant works on mice in hours, not weekson January 18, 2021 at 4:00 pm
“That means it may work in patients who are unresponsive to other types of drugs and it lays the foundation for the development of a new class of fast-acting antidepressants that target the same ...
- Psychology Todayon January 12, 2021 at 3:59 pm
Pharmaceutical giant Johnson & Johnson gained U.S. Food and Drug Administration (FDA) approval in 2019 for its fast-acting antidepressant chemical compound that mirrors ketamine. “The regulatory ...
- Depression Resource Center Newson January 11, 2021 at 4:00 pm
Medscape Medical News, September 30, 2010 ACEP Ketamine Offers Fast-Acting Alleviation of Acute Depression in ED Setting A single intravenous bolus dose of ketamine offered rapid alleviation of ...
- Tal Medical Gets NIMH Backing for Fast-Acting Depression Therapyon January 9, 2021 at 3:59 pm
If you’re suffering from depression, then going to a doctor’s office, sticking your head into a magnetic coil and getting your brain electronically stimulated might not seem all that appetizing.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Antidepressants won't help with back pain and osteoarthritis, says studyon January 24, 2021 at 12:17 am
A recent study suggested that contrary to the common belief stimulant medication does not have any effect on chronic back pain and hip and knee osteoarthritis.
- Why are doctors STILL failing to tell patients they may never be able to give up antidepressants?on January 23, 2021 at 2:04 pm
Reduced doses of antidepressants - or just quitting the pills - can trigger insomnia, suicidal thoughts and convulsions, even if they had been taken for as little as three months.
- Little Help, Possible Harm of Antidepressants for Musculoskeletal Painon January 22, 2021 at 6:17 am
Antidepressants are of little help and may possibly be harmful in the treatment of musculoskeletal pain, new research suggests. Results of a systematic review and meta-analysis show that serotonin and ...
- Antidepressants ineffectual for back pain and osteoarthritison January 21, 2021 at 1:19 am
Most clinical practice guidelines recommend antidepressants for long term (chronic) back pain and hip and knee osteoarthritis A study published by the British Medical Journal (BMJ) provides evidence ...
- Antidepressants are not effective for treating back pain, osteoarthritis, shows studyon January 20, 2021 at 8:34 pm
Antidepressants are commonly used worldwide to treat pain, however new research from the University of Sydney shows they offer little to no help for people suffering chronic back pain and ...